Jerez, Yolanda
Márquez-Rodas, Ivan
Aparicio, Inmaculada
Alva, Manuel
Martín, Miguel http://orcid.org/0000-0002-2606-9538
López-Tarruella, Sara
Article History
First Online: 10 December 2019
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript. Support has been received for the style correction by EditageOnline<sup>TM</sup>.
: Yolanda Jerez has a consultant or advisory role at Novartis, Pfizer, Roche, and AstraZeneca and has received speaker honoraria from Roche, Novartis, and AstraZeneca and travel grants from Roche, Novartis, Pfizer, and Teva. Ivan Márquez-Rodas has a consultant or advisory role and travel grants from BMS, MSD, Novartis, Pierre Fabre, Roche, Regeneron, Sanofi, Amgen, Bioncotech, MERCK-serono, Incyte. Miguel Martín has received research grants from Roche, PUMA, and Novartis; consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, and Pfizer; and speakers’ honoraria from AstraZeneca, Amgen, Roche/Genentech, Novartis, Daiichi Sankyo, and Pfizer. Sara López-Tarruella has a consultant or advisory role at Celgene, Novartis, Pierre Fabre, Pfizer, Roche, Eisai, and Lilly and an AZ travel grant from Celgene, Pfizer, Roche, and MSD. Inmaculada Aparicio and Manuel Alva declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.